Menu

Tasmanian Devil Cancer Immunotherapy

Researchers in Australia claim to have successfully used immunotherapy to treat devil facial tumor disease.

Mar 13, 2017
Bob Grant

WIKIMEDIA, KERESHScientists working to slow the spread of a deadly facial cancer through populations of the Tasmania’s iconic marsupial Sarcophilus harrisii, or the Tasmanian devil, have announced progress by injecting live cancer cells into individuals with the disease. The study, which reports that some golf-ball-size tumors disappeared entirely after the injections, was published Thursday (March 9) in Scientific Reports.

“When we saw those tumors get smaller it was so exciting,” University of Tasmania immunologist Greg Woods told BBC News. “This is almost a eureka moment for us because it's the first time we can say for sure that it was the immunotherapy that was making the tumor shrink.”

See: “Tasmanian Devils Developing Resistance to Transmissible Cancer

The team of researchers, which included scientists from the United Kingdom and Denmark, administered devil facial tumor disease (DFTD) cells to six animals with the cancer. The cells, which expressed the surface major histocompatibility complex (MHC)-I molecule typically missing from DFTD tumors, allowed immune cells to infiltrate and shrink the cancerous growths. “We used the cancer cells, cultured them in a laboratory, and made them express genes that made them become visible to the devils' immune systems,” Woods told the Australian Broadcasting Corporation.

The findings may point the way toward a more effective vaccine that could protect remaining devil populations from DFTD. “The current immunization process uses dead (tumor) cells, whereas this one used live cells, so if we somehow get a combination of the two then we might have a better vaccine,” Woods said.

But protecting wild populations with vaccines is not so easy. “It's not feasible to track down and immunize every animal in the wild,” Bruce Lyons, a University of Tasmania researcher and coauthor told BBC News.

See: “The Devil’s Details

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.